Annex 1 of the EU GMP guidelines sets out the requirements for manufacturing sterile medicinal products. Its major revision, published in August 2022, took effect on 25 August 2023, with one provision on lyophiliser loading following a year later. It is also adopted by PIC/S and applies in the UK.
The revised Annex 1 puts quality risk management and a site-wide contamination control strategy at its centre. It covers premises and cleanroom classification (grades A to D), barrier technologies such as isolators and RABS, personnel training and gowning qualification, utilities such as water for injection and clean steam, sterilisation and filter integrity testing, aseptic process simulation, environmental and process monitoring, container closure integrity and visual inspection.
Why it matters in GMP
Sterile products carry the highest risk to patients if something goes wrong, and Annex 1 inspections are detailed. The revision raised expectations on documentation linking controls to risks, on monitoring and trending, and on the evidence that every element of the strategy works.
- Document a contamination control strategy and keep it current.
- Qualify cleanrooms, lines and people, and keep that status visible.
- Investigate and trend monitoring excursions and process failures.
How Swat iQua Suite handles it
Swat iQua Suite covers the Annex 1 controls for sterile and injectable manufacturing: a versioned CCS, media fill protocols and runs, sterilisation cycles with biological and chemical indicators and filter integrity tests, lyophilisation, container closure integrity, visual inspection, utilities monitoring and environmental monitoring. A sterile step cannot start unless the room is ready, no excursion is open, the operator is gowning-qualified and the line has a current passing media fill, and sterile failures block batch release.